Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant
works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay
multiple myeloma from coming back after a stem cell transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals